pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker BTAI. Primary therapeutic focus areas include Agitation, Agitation,Psychomotor, Alcohol Use Disorder (AUD), Sc
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
Quick answer
BioXcel Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker BTAI. Primary therapeutic focus areas include Agitation, Agitation,Psychomotor, Alcohol Use Disorder (AUD), Schizophrenia, Bipolar I Disorder. NovaPharmaNews links 17 clinical program(s), 0 drug profile(s), and 18 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (6), phase 1 (5), phase 3 (4).
Company snapshot
Biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence
- 17 active pipeline program(s) linked via ClinicalTrials.gov.
- 18 US patent(s) indexed to this assignee profile.
- 17 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for BioXcel Therapeutics. Not investment advice.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for BioXcel Therapeutics.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for BioXcel Therapeutics.
- Clinical update
- Clinical update
Sublingual film containing Dexmedetomidine (BXCL501) — Phase 3
- Clinical update
Sublingual film containing dexmedetomidine (BXCL501) — Phase 3
- Clinical update
- Clinical update
Sublingual film containing BXCL501 (Dexmedetomidine) — Phase 1
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is BioXcel Therapeutics?
-
Is BioXcel Therapeutics publicly traded?
-
What drugs does BioXcel Therapeutics develop or market?
-
What are the latest developments for BioXcel Therapeutics?
-
What therapeutic areas does BioXcel Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.